Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria |
This Phase 2b study was an open label randomized controlled study conducted in two parts and which enrolled more than 500 patients with acute uncomplicated malaria due to Plasmodium falciparum infection |
BASEL, Switzerland, September 30, 2021/ -- Novartis (https://www.Novartis.com) and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria; In the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine met the primary study objective; The positive Phase 2b results for the next generation antimalarial therapy support continued development of the combination Distributed by APO Group on behalf of Novartis. |
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506